Launching a daratumumab self-administration and homecare programme
Published:
Around 40% of patients receiving daratumumab are now using the homecare service, with 60% of those patients self-administering. Find out how the programme was developed and what it has meant for patients and day unit capacity.
Sign up and become a member of the Myeloma UK HCP Hub
Access exclusive content like this and join in the conversation.
Already have an account?